PRVB News and Press, Provention Bio Inc. From 08/05/19

OLDWICK, N.J. , Aug. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Ther...

Thoughts about performance presentation Due to a mix of personal, professional and technical reasons more than 3 weeks have passed since my last article "Do Not Sell In May (June) And Go Away; Look At These Buy Candidates" was published. There have been interesting developments both in the...

GHENT, Belgium, July 1, 2019 /PRNewswire/ --   ActoBio Therapeutics, Inc. , a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, has announced that it will ...

GHENT, Belgium, July 1, 2019 /PRNewswire/ --   ActoBio Therapeutics, Inc. , a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, has announced that it will ...

"Facts do not cease to exist because they are ignored.” ― Aldous Huxley Last week was a good one for investors as the S&P 500 hit an all-time high. Biotech had a particularly strong performance on the heels of the $11 billion acquisition of Array Biopharma ( ARRY ) by...

It is a great time to be investing in healthcare stocks. Sentiment is not overly positive and Medicare For All remains an overhang (it will not be implemented within the next ten years), yet I maintain that the outlook for continued growth, driven by the prevalence of chronic disease and demog...

Provention Bio ( PRVB ) announced positive results in a study known as "At Risk" to delay patients from gaining Type 1 diabetes (T1D). Such substantial results were presented at the Scientific Sessions of the 79 th Annual American Diabetes Association ((ADA)) meeting. The bottom line is...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was on the decline last week, dropping from 3,269.13 points on Monday (June 10) to 3,238.69 points as of 2:08 p.m. EDT on Friday (June 14). Last week, Provention Bio (NASDAQ: PRVB ) announced a public offering of its common stock on Monday...

It's far better to buy a wonderful company at a fair price, than a fair company at a wonderful price. - Warren Buffett Aside from the outsized return in the long haul, another reason that attracted me to bioscience investing is the mega profits that can come in just one trading session. Th...

DryShips (NASDAQ: DRYS ) +26%  after merger offer . More news on: DryShips Inc., Red Robin Gourmet Burgers, Inc., RH, Stocks on the move, Read more ...